Mason W Freeman
Overview
Explore the profile of Mason W Freeman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
3623
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Antman E, Freeman M, Golan D, Kitterman R, McKenna E, Parrish J, et al.
J Clin Transl Sci
. 2021 Aug;
5(1):e137.
PMID: 34367681
Implementation of clinically useful research discoveries in the academic environment is challenged by limited funding for early phase proof-of-concept studies and inadequate expertise in product development and commercialization. To address...
12.
Zabaleta N, Dai W, Bhatt U, Chichester J, Sanmiguel J, Estelien R, et al.
bioRxiv
. 2021 Jan;
PMID: 33442684
The SARS-CoV-2 pandemic has affected more than 70 million people worldwide and resulted in over 1.5 million deaths. A broad deployment of effective immunization campaigns to achieve population immunity at...
13.
Halvorsen Y, Walford G, Thurber T, Russell H, Massaro M, Freeman M
Diabetes Obes Metab
. 2019 Nov;
22(4):566-573.
PMID: 31749238
Aim: To compare the safety and efficacy of bexagliflozin administered as monotherapy at three dosage strengths over a 12-week period to patients with type 2 diabetes who were either naïve...
14.
Freeman M, Guidon A, Arvikar S
N Engl J Med
. 2019 Oct;
381(17):1694.
PMID: 31644864
No abstract available.
15.
Freeman M, Singh A, Guidon A, Arvikar S, Goldstein R, Clement N
N Engl J Med
. 2019 Jul;
381(3):275-283.
PMID: 31314973
No abstract available.
16.
Halvorsen Y, Walford G, Massaro J, Aftring R, Freeman M
Diabetes Obes Metab
. 2019 Jul;
21(11):2496-2504.
PMID: 31297965
Aim: To explore the safety and effectiveness of extended exposure to bexagliflozin as a monotherapy for type 2 diabetes. Methods: Adults with diabetes (n = 288) from the USA, Colombia...
17.
Halvorsen Y, Lock J, Zhou W, Zhu F, Freeman M
Diabetes Obes Metab
. 2019 Jun;
21(10):2248-2256.
PMID: 31161692
Aim: To compare the relative safety and effectiveness of bexagliflozin and sitagliptin as adjuncts to metformin for the treatment of adults with type 2 diabetes. Methods: Participants (n = 386)...
18.
Allegretti A, Zhang W, Zhou W, Thurber T, Rigby S, Bowman-Stroud C, et al.
Am J Kidney Dis
. 2019 May;
74(3):328-337.
PMID: 31101403
Rationale & Objective: Hyperglycemia exacerbates the progression of chronic kidney disease (CKD), but most glucose-lowering therapies do not address morbidities associated with CKD. Sodium/glucose cotransporter 2 (SGLT2) inhibitors offer potential...
19.
Pitt B, Bakris G, Weir M, Freeman M, Lainscak M, Mayo M, et al.
ESC Heart Fail
. 2018 May;
5(4):592-602.
PMID: 29767459
Aims: Chronic kidney disease (CKD) in heart failure (HF) increases the risk of hyperkalaemia (HK), limiting angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) use. Patiromer is a sodium-free,...
20.
Antman E, Di Corleto P, Freeman M, Ganz T, Golan D, Kitterman R, et al.
Nat Rev Drug Discov
. 2017 Aug;
16(10):663-664.
PMID: 28775338
No abstract available.